Oncohematology
The identification of the molecular alterations present in oncohematological diseases is essential, in many cases, to confirm the diagnosis, establish a prognosis, facilitate the selection of treatment for each patient and follow up on the disease.
NIMGenetics offers from conventional studies, such as the conventional karyotype and FISH, to the most advanced technologies such as CGH arrays and NGS panels for the study of these pathologies
KaryoNIM® Leukemia
Genomic platform designed by NIMGenetics for the identification of biomarkers in chronic lymphatic leukemia (CLL), which combines the technology of array-CGH and SNParray.
- Array-CGH has proven to be the most effective technology in this type of leukemia, increasing the diagnostic yield 20% with respect to FISH. This is due mainly to its greater ability to detect and delimit CNVs, as well as to the fact that array-CGH simultaneously examines the whole genome, and not only the regions included in the studies using FISH.
- Its powerful design provides complete coverage of both the classical regions and other genes of interest in the prognosis of CLL, showing a high detection capacity (130 kb) in both contexts. Likewise, the genes included in the Cancer Consensus are fully covered.
- The SNPs provide, additionally, the ability to give information on loss of heterozygosity and clonality.
KaryoNIM® Leukemia facilitates the most up-to-date genetic diagnosis of CLL, in accordance with international guidelines and the most advanced laboratories in the world.
Reference: ONC1003
Delivery of results: 15 working days after receipt of sample
Molecular Diagnosis
Molecular biology allows the presence and / or quantification of fusion proteins secondary to chromosomal rearrangements / translocations and the identification of mutations in various genes involved in haematological malignancies to be determined.
Cytogenetic Diagnosis
Conventional and molecular cytogenetics are currently the techniques of first choice in the genetic diagnosis of various hematological diseases. The results of these studies are essential for the proper classification of these entities. Its value as a prognostic biomarker has been demonstrated in various haemopathies such as acute leukemias, myelodysplastic syndromes, chronic lymphocytic leukemia or multiple myeloma, among others.
Diagnosis by FISH
Conventional and molecular cytogenetics are currently the techniques of first choice in the genetic diagnosis of various hematological diseases. The results of these studies are essential for the proper classification of these entities. Its value as a prognostic biomarker has been demonstrated in various haemopathies such as acute leukemias, myelodysplastic syndromes, chronic lymphocytic leukemia or multiple myeloma, among others.
